勃林格殷格翰survodutide的研究结果显示，64.5%的F2和F3期纤维化患者的肝纤维化得到突破性改善且MASH无恶化
勃林格殷格翰survodutide的研究结果显示，64.5%的F2和F3期纤维化患者的肝纤维化得到突破性改善且MASH无恶化
Region switcher
Use the region switcher to change your region and language preferences
返回
Change region and language
Search for a region
-
Global
-
Albania
-
Algeria
-
Argentina
-
Australia
-
Austria (Österreich)
-
Bahrain
-
Belarus
-
Belgium (Belgique)
-
Bosnia and Herzegovina
-
Botswana
-
Brazil (Brasil)
-
Bulgaria (България)
-
Cambodia
-
Canada
-
Chile
-
Colombia
-
Croatia
-
Czechia (Česko)
-
Denmark (Danmark)
-
Ecuador
-
Egypt
-
Estonia
-
Ethiopia
-
Finland (Suomi)
-
France
-
Germany (Deutschland)
-
Ghana
-
Greece (Ελλάδα)
-
Hong Kong (China)
-
Hungary (Magyarország)
-
India
-
Indonesia
-
Iran
-
Ireland
-
Israel
-
Italy (Italia)
-
Japan (日本)
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea (대한민국)
-
Kuwait
-
Latin America
-
Latvia
-
Lebanon
-
Libya
-
Lithuania
-
Mainland China (中国)
-
Malawi
-
Malaysia
-
Malta
-
Mauritius
-
Mexico (México)
-
Middle East and North Africa
-
Moldova
-
Morocco
-
Namibia
-
Netherlands (Nederland)
-
New Zealand
-
Nigeria
-
Norway (Norge)
-
Oman
-
Pakistan
-
Paraguay
-
Peru
-
Poland (Polska)
-
Portugal (Portugalia)
-
Qatar
-
Romania (România)
-
Russia (Россия)
-
Saudi Arabia
-
Serbia
-
Seychelles
-
Singapore
-
Slovakia (Slovensko)
-
Slovenia
-
Somalia
-
South Africa
-
Spain (España)
-
Sub-Sahara Africa
-
Sudan
-
Sweden (Sverige)
-
Switzerland (Schweiz)
-
Syria
-
Taiwan (China) (台灣)
-
Tanzania
-
Thailand
-
Tunisia
-
Turkey
-
Uganda
-
Ukraine (Україна)
-
United Arab Emirates
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Zimbabwe
Not what you are looking for?
Check out the global boehringer-ingelheim.com
请扫码关注我们
勃林格殷格翰官方
勃林格殷格翰HR
勃林格殷格翰动保